Woebot Health Receives FDA Breakthrough Device Designation for Postpartum Depression Treatment
WB001 is the first digital therapeutic designed to reduce the burden of postpartum depression SAN FRANCISCO–(BUSINESS WIRE)– Woebot Heath, a pioneer in the development of relational technologies and tools to support mental health, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s digital therapeutic for the […]